Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01424345 · ClinicalTrials.gov registry record · Phase 4
The Role of ImmuKnow® in the Management of Immunosuppressants in the Renal Transplant Patient
A Phase 4 study, sponsored by CAMC Health System.
- Terminated
- Registry status
- Phase 4
- Development phase
- 4
- Enrollment target
NCT01424345: Clinical Trial Phase 4 study, sponsored by CAMC Health System.
NCT01424345 is a Phase 4 study that was terminated before completion, run by CAMC Health System. The registered enrollment target is 4 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01424345, a Phase 4 study, was terminated before completion, sponsored by CAMC Health System.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 4 participants
- Enrollment target
Study Summary
The purpose of this study is to demonstrate whether there are any outcome benefits of a serial ImmuKnow assays in the management of de novo renal transplant recipients.
Primary Outcome
The combo-infection is defined as: If a patient either has new onset culture/or serology/or PCR positive bacterial or viral infections; or moderate neutropenia (absolute netrophile count \< 1000/microL) or need GCS-F injection or has fever \>38.5 % for longer than 24 hrs then he/she is called to have combo- infection. Percentage of such patients will be compared in Immuknow vs. control group.
Interventions
- DRUG adjustment of immunosuppressant dosages
- DRUG adjustment of the dosages of immunosuppressants
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2011-12 |
| Est. Completion | 2012-07 |
| Phase | Phase 4 |
Why NCT01424345 stopped before completion
NCT01424345 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 4 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 2 interventions - of which adjustment of immunosuppressant dosages is the first listed.
NCT01424345 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01424345 about?
NCT01424345 is a clinical study titled "The Role of ImmuKnow® in the Management of Immunosuppressants in the Renal Transplant Patient". The purpose of this study is to demonstrate whether there are any outcome benefits of a serial ImmuKnow assays in the management of de novo renal transplant recipients.
What is the current status of trial NCT01424345?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 4 participants. The study started on 2011-12. Estimated completion is 2012-07.
What interventions are being tested in trial NCT01424345?
The interventions under investigation include: adjustment of immunosuppressant dosages (DRUG), adjustment of the dosages of immunosuppressants (DRUG).
Who is sponsoring clinical trial NCT01424345?
This trial is sponsored by CAMC Health System, which has 28 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01424345's enrollment target sits among peer trials
4 1994th of 2000 higher than 6 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia